Evidence map›Paper›PMID 37070097›Full record

ArticlePeerJ2023

High circulating fibroblast growth factor-21 levels as a screening marker in fatty pancreas patients.

Fei Han, Ling Yin, Xiaoping Yu, Renyan Xu, Mingxiang Tian, Xinnong Liu, Lu Zhou, Lianghao Hu, Weijuan Gong, Weiming Xiao and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Fei Han *Dalian Medical University, Dalian, China.
Ling Yin *Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Xiaoping YuDepartment of Health Promotion Center, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Renyan XuDepartment of Health Promotion Center, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Mingxiang TianDepartment of Health Promotion Center, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Xinnong LiuInstitute of Digestive Diseases, Yangzhou University, Yangzhou, China.
Lu ZhouDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Lianghao HuDepartment of Gastroenterology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Weijuan GongDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Weiming XiaoDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Guotao LuDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Guanghuai YaoDepartment of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou, China.
Yanbing DingDalian Medical University, Dalian, China.
Yangzhou University · CNChanghai Hospital · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The study aimed to detect the serum levels of fibroblast growth factor-21 (FGF-21) in fatty pancreas (FP) patients and to investigate their potential clinical value. Methods: We screened patients with FP using transabdominal ultrasound. The anthropometric, biochemical and serum levels of FGF-21 were compared between the FP group and the normal control (NC) group. A receiver operating characteristic (ROC) curve was used to evaluate the predictive value of serum FGF-21 for FP patients. Results: Compared with the NC group, body mass index, fasting blood glucose levels, uric acid levels and cholesterol levels of the FP group were significantly higher, while the high-density lipoprotein level was lower. In addition, levels of serum FGF-21, resistin, leptin and tumor necrosis factor- Conclusion: Serum FGF-21 was closely related to fatty pancreas. Detecting serum FGF-21 levels may help identify the population susceptible to FP.

Indexed as

Fibroblast Growth FactorsPancreatic DiseasesAdiponectinHumansLeptinPancreasAdiponectinfibroblast growth factor 21Fibroblast Growth FactorsLeptinAdipocytokineFatty pancreasFibroblast growth factor-21Metabolic diseasesPrognostic marker

Identifiers

PMID37070097
PMCPMC10105565
OpenAlexW4365146797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.